HIV-1 drug susceptibilities and reverse transcriptase mutations in patients receiving combination therapy with didanosine and delavirdine

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 14, Issue 2, 1997, Pages 136-144

  Demeter, L M ^a   Meehan, P M ^b   Morse, G ^c   Gerondelis, P ^a   Dexter, A ^a   Berrios, L ^a   Cox, S ^d   Freimuth, W ^d   Reichman, R C ^a,e  

^a UNIVERSITY OF ROCHESTER   (United States)

^b HARVARD UNIVERSITY   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

^d PFIZER INC   (United States)

^e UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Combination therapy; Drug resistance; Human immunodeficiency virus type 1 (HIV 1) infection; Nonnucleoside reverse transcriptase inhibitors

Indexed keywords

DELAVIRDINE; DIDANOSINE; RNA DIRECTED DNA POLYMERASE;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFECT; DRUG POTENTIATION; ENZYME INHIBITION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; VIRUS MUTATION; VIRUS RESISTANCE;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0031052425     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199702010-00006     Document Type: Article

References (37)

1. Richman D, Rosenthal AS, Skoog M, et al. BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudine. Antimicrob Agents Chemother 1991;35:305-8.
2. Merluzzi VJ, Hargrave KD, Labadia M, et al. Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science 1990;250:1411-3.
3. Pauwels R, Andries K, Desmyter J, et al. Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature 1990;343:470-4.
4. Debyser Z, Pauwels R, Andries K, et al. An antiviral target on reverse transcriptase of human immunodeficiency virus type 1 revealed by tetrahydroimidazo-[4,5,1-jk[1,4]benzodiazepin-2(1H)-one and -thione derivatives. Proc Natl Acad Sci USA 1991;88:1451-5.
5. Carroll SS, Olsen DB, Bennett, CD, et al. Inhibition of HVI-1 reverse transcriptase by pyridinone derivatives: potency, binding characteristics, and effect of template sequence J Biol Chem 1993;268:276-81.
6. Goldman ME, Nunberg JH, O'Brien JA, et al. Pyridinone derivatives: specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity. Proc Natl Acad Sci USA 1991;88:6863-7.
7. Romero DL, Busso M, Tan C-K, et al. Nonnucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency type 1 replication. Proc Natl Acad Sci USA 1991;88:8806-10.
8. Dueweke TJ, Poppe SM, Romero DL, et al. U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication. Antimicrob Agents Chemother 1993;37:32767.
9. Spence RA, Kati WM, Anderson KS, Johnson KA. Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science 995;267:988-93.
10. Kohlstaedt LA, Wang J, Friedman JM, Rice PA, Steitz TA. Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 1992; 256: 1783-90.
11. Cohen KA, Hopkins J, Ingraham RH, et al. Characterization of the binding site for nevirapine (BI-RG-587), a nonnucleoside inhibitor of human immunodeficiency virus type-1 reverse transcriptase. J Biol Chem 1991;266:14670-4.
12. Tantillo, C, Ding, J, Jacobo-Molina A, et al. Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. J Mol Biol 1994;243:369-87.
13. Richman D, Shih C-K, Lowy I, et al. Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. Proc Natl Acad Sci USA 1991;88:11241-5.
14. Nunberg JH, Schlief WA, Boots EJ, et al. Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors J Virol 1991;65:4887-92.
15. Saag MS, Emini EA, Laskin OL, et al. A short-term clinical evaluation of L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase. N Engl J Med 1993;329:1065-72.
16. Richman DD, Havlir D, Corbeil J, et al. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol 1994;68:1660-6.
17. Vandamme AM, Debyser Z, Pauwels R, et al. Characterization of HIV-1 strains isolated from patients treated with TIBO R82913. AIDS Res Hum Retrovirus 1994;10:39-46.
18. Staszewski S, Massari FE, Kober A, et al. Combination therapy with zidovudine prevents selection of human immunodeficiency virus type 1 variants expressing high-level resistance to L-697,661, a nonnucleoside reverse transcriptase inhibitor. J Infect Dis 1995;171:1159-65.
19. Byrnes WV, Sardana VV, Schleif WA, et al. Comprehensive mutant enzyme and viral variant assessment of human immunodeficiency type 1 reverse transcriptase resistance to nonnucleoside inhibitors. Antimicrob Agents Chemother 1993; 37:1576-9.
20. Been-Tiktak AMM, Joly V, Sitbon G, et al. Combination therapy with delavirdine mesylate (DLV) and AZT: virology data from an European phase II trial. J Acquir Immune Defic Syndr Hum Retrovir 1995;10:S23-4.
21. Wathen LK, Freimuth WW, Batts DH, Cox SR. Phenotypic and genotypic characterization of HIV-1 viral isolates from patients treated with combined AZT and delavirdine mesylate (DLV) therapy. Third International Workshop on HIV Drug Resistance, Kuai, HI, July 1995, p 42.
22. Reichman RC, Morse OD, Demeter LM, et al. Phase I study of atevirdine, a nonnucleoside reverse transcriptase inhibitor, in combination with zidovudine for human immunodeficiency virus type 1 infection. J Infect Dis 1995;171:297-304.
23. Demeter LM, Resnick L, Nawaz T, Timpone JG, Batts D, Reichman RC. Phenotypic and Genotypic analysis of atevir0ine susceptibility of HIV-1 isolates obtained from patients receiving atevirdine monotherapy in a phase I clinical trial (ACTG 187): comparison to patients receiving combination therapy with atevirdine and zidovudine. Third Workshop on Viral Resistance, Gaithersburg, MD, Sept 1993.
24. Larder BA. 3́-Azido-3́-deoxythymidine resistance sup1 pressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 1992;30:2664-9.
25. Byrnes VW, Emini EA, Schleif WA, et al. Susceptibilities of human immunodeficiency virus type 1 enzyme and viral variants expressing multiple resistance-engendering amino acid substitutions to reverse transcriptase inhibitors. Antimicrob Agents Chemother 1994;38:1401-7.
26. Dueweke TJ, Pushkarskaya T, Poppe SM, et al. A mutation in reverse transcriptase of bis(heteraryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors. Proc Natl Acad Sci USA 1993;90:4713-7.
27. Demeter LM, Shafer RW, Para M, et al. Delavirdine susceptibility of HIV-1 isolates obtained from patients receiving DLV monotherapy. J Acquir Immune Defic Syndrom Hum Retrovir 1995;10:S11.
28. Cox SR, Cohn SE, Greisberger C, et al. Evaluation of the steady-state pharmacokinetic interaction between didanosine and delavirdine mesylate in HIV-positive patients. 35th interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA 1995, Abstr 131.
29. Hollinger FB, Bremer JW, Myers LE, Gold JWM, McQuay L. NIH/NIAID/DAIDS/ACTG virology Laboratories. Standardization of sensitive human immunodeficiency virus coculiure procedures and establishment of a multicenter quality assurance program for the AIDS Clinical Trials Group. J Clin Microbiol 1992;30:1787-94.
30. Japour AJ, Mayers DL, Johnson VA, et al. Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. Antimicrob Agents Chemother 1993;37:1095-101.
31. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
32. Larder BA, Boucher CAB. Polymerase chain reaction detection of human immunodeficiency virus drug resistance mutations. In: Persing DH, Smith TF, Tenover FC, White TJ, eds. Diagnostic molecular microbiology. Principles and applications. Washington, DC: American Society for Microbiology, 1993:527-33.
33. De Remer M, D'Ambrosio R, Morse GD. Didanosine measurement by radioimmunoassay. Antimicrob Agents Chemother 1996;40:1331-4.
34. Staton BA, Johnson MG, Friis JM, Adams WJ. Simple, rapid and sensitive high-performance liquid Chromatographic determination of delavirdine and its N-desisopropyl metabolite in human plasma. J Chromatogr 1995;8:99-106.
35. Shirasaka T, Kavlick MF, Ueno T, et al. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc Natl Acad Sci USA 1995;92: 2398-402.
36. Shafer RW, Kozal MJ, Winters MA, et al. Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations. J Infect Dis 1994;169:722-9.
37. Boucher CAB, van Leeuwen R, Kellam P, et al. Effects of discontinuation of zidovudine treatment on zidovudine sensitivity of human immunodeficiency virus type 1 isolates. Antimicrob Agents Chemother 1993;37:1525-30.